drugset

drugset / Trial / NCT05864365

A Biomarker Study of ATH434 in Participants With MSA

NCT05864365 ↗

Phase 2 Completed 10 enrolled Alterity Therapeutics

NaSingle-groupOpen-labelTreatment

Summary

This study will assess the safety and efficacy of ATH434 in participants with a clinical diagnosis of Multiple System Atrophy

Timeline

Start: 2023-05-23
Primary completion: 2025-02-26
Completion: 2025-02-26

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PBT-434	Small molecule	—	Oral

Indications